NO915116L - Ikke-glykosylerte human-interleukin-3-analogproteiner - Google Patents

Ikke-glykosylerte human-interleukin-3-analogproteiner

Info

Publication number
NO915116L
NO915116L NO91915116A NO915116A NO915116L NO 915116 L NO915116 L NO 915116L NO 91915116 A NO91915116 A NO 91915116A NO 915116 A NO915116 A NO 915116A NO 915116 L NO915116 L NO 915116L
Authority
NO
Norway
Prior art keywords
humane
glycosylated
interleukin
analog proteins
analog
Prior art date
Application number
NO91915116A
Other languages
English (en)
Other versions
NO301482B1 (no
NO915116D0 (no
Inventor
David L Urdal
Helmut Sassenfeld
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO915116D0 publication Critical patent/NO915116D0/no
Publication of NO915116L publication Critical patent/NO915116L/no
Publication of NO301482B1 publication Critical patent/NO301482B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/823—Lower fungi, e.g. mold
    • Y10S530/824—Yeasts
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO915116A 1989-06-30 1991-12-27 Fremgangsmåte for fremstilling av renset rekombinant human-IL-3-analogprotein som omfatter Met3huIL-3(Pro8Asp15Asp70), isolert DNA-sekvens, rekombinant ekspresjonsvektor og gjærvertscelle NO301482B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/374,667 US5128450A (en) 1989-06-30 1989-06-30 Nonglycosylated human interleukin-3 analog proteins
PCT/US1990/003345 WO1991000350A1 (en) 1989-06-30 1990-06-13 Nonglycosylated human interleukin-3 analog proteins

Publications (3)

Publication Number Publication Date
NO915116D0 NO915116D0 (no) 1991-12-27
NO915116L true NO915116L (no) 1992-02-28
NO301482B1 NO301482B1 (no) 1997-11-03

Family

ID=23477728

Family Applications (1)

Application Number Title Priority Date Filing Date
NO915116A NO301482B1 (no) 1989-06-30 1991-12-27 Fremgangsmåte for fremstilling av renset rekombinant human-IL-3-analogprotein som omfatter Met3huIL-3(Pro8Asp15Asp70), isolert DNA-sekvens, rekombinant ekspresjonsvektor og gjærvertscelle

Country Status (12)

Country Link
US (1) US5128450A (no)
EP (1) EP0482013B1 (no)
JP (1) JPH04506342A (no)
AT (1) ATE138099T1 (no)
AU (1) AU630207B2 (no)
CA (1) CA2033182A1 (no)
DE (1) DE69027031T2 (no)
DK (1) DK0482013T3 (no)
ES (1) ES2090135T3 (no)
FI (1) FI916077A0 (no)
NO (1) NO301482B1 (no)
WO (1) WO1991000350A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5705362A (en) * 1992-05-25 1998-01-06 Gist-Brocades, N.V. Modified signal sequences
US5463029A (en) * 1992-11-23 1995-10-31 Immunex Corporation Purification of fusion proteins comprising GM-CSF and IL-3
US6153183A (en) * 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6361976B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5604116A (en) 1992-11-24 1997-02-18 G. D. Searle & Co. Interleukin-3 (IL-3) multiple mutation polypeptides, recombinant production of the same, and corresponding therapeutic methods
US6403076B1 (en) 1992-11-24 2002-06-11 S. Christopher Bauer Compositions for increasing hematopoiesis with interleukin-3 mutants
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
EP0728013A4 (en) * 1993-11-10 1999-09-15 Jackson H M Found Military Med COMPOSITION AND METHOD FOR THE STIMULATION OF THE ANTIBODY RELEASE BY THROUGH LYMPHOCYTES
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
JP4790911B2 (ja) 1999-01-13 2011-10-12 アルケミア オンコロジー ピーティワイ リミテッド 薬物の効力を増強するための組成物および方法
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2002069977A1 (en) 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
CA2458856C (en) * 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
JP4212827B2 (ja) * 2002-05-16 2009-01-21 シスメックス株式会社 骨髄液有核細胞自動分析方法
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
EP1848738A1 (en) * 2005-01-25 2007-10-31 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EA013877B1 (ru) * 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
JP5628544B2 (ja) * 2010-04-07 2014-11-19 株式会社豊田中央研究所 クロストリジウム・サーモセラム由来のタンパク質複合体を構築するためのタンパク質及びその利用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
US4877729A (en) * 1986-07-14 1989-10-31 Genetics Institute, Inc. Recombinant DNA encoding novel family of primate hematopoietic growth factors
EP0790307A1 (en) * 1986-12-16 1997-08-20 Gist-Brocades B.V. Molecular cloning and expression of human IL-3
WO1988004691A1 (en) * 1986-12-16 1988-06-30 Gist-Brocades N.V. Molecular cloning and expression of human il-3
AU1496688A (en) * 1987-01-20 1988-08-10 Immunex Corporation Human interleukin-3 proteins
OA09736A (en) * 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".
EP0425536A4 (en) * 1988-07-20 1992-01-02 Immunex Corporation Nonglycosylated human interleukin-3 compositions

Also Published As

Publication number Publication date
US5128450A (en) 1992-07-07
CA2033182A1 (en) 1990-12-31
WO1991000350A1 (en) 1991-01-10
DE69027031D1 (de) 1996-06-20
DE69027031T2 (de) 1996-12-19
NO301482B1 (no) 1997-11-03
AU630207B2 (en) 1992-10-22
AU5821690A (en) 1991-01-17
EP0482013A1 (en) 1992-04-29
NO915116D0 (no) 1991-12-27
JPH04506342A (ja) 1992-11-05
EP0482013B1 (en) 1996-05-15
ES2090135T3 (es) 1996-10-16
ATE138099T1 (de) 1996-06-15
FI916077A0 (fi) 1991-12-20
DK0482013T3 (da) 1996-06-03

Similar Documents

Publication Publication Date Title
NO915116L (no) Ikke-glykosylerte human-interleukin-3-analogproteiner
SE7705432L (sv) Polypeptid och sett for dess framstellning
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
DE69129248D1 (de) Peptide mit Endothelin antagonistischer Aktivität, deren Herstellung und pharmazeutische Zusammensetzungen
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
NO952744D0 (no) Cytokinbegrensende midler
EP1884524A3 (en) Pharmaceutical composition for treatment of diseases caused by IL-6 production
CA2009890A1 (en) Valproic acid
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
RS20090086A (en) Nucleoside analogs with carobxamidine modified monocyclic base
YU174490A (sh) Novi estri tienil-karboksilne kiseline sa aminoalkoholima, njihova kvaterna jedinjenja kao i pripremanje i primena tih jedinjenja
NZ329970A (en) Use of IFN-beta mutein derivatives for treating viral infections
PT89534A (pt) Processo para a preparacao de composicoes farmaceuticas anticoagulantes contendo como ingrediente activo proteina c ou proteina c activada combinada com heparina
LV10954A (lv) Benzimidazola atvasinajumi to iegusanas panemiens un tos saturosa farmaceitiska kompozicija
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
ES2173858T3 (es) Analogos de huperzina a.
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
HUP9700826A1 (hu) Peptikus fekély elleni gyógyászati készítmények
ES2138973T3 (es) Muteinas de il-6 exentas de cisteina.
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
ES8705763A1 (es) Procedimiento para preparar nuevas formulaciones de gel parafines terapeuticos y diagnosticos
DK0427124T3 (da) Antacidatabletter
ES2032757T3 (es) Inyecciones que contienen alcohol poliprenilico y el uso de estas.
KR960700741A (ko) 인터페론치료에 대한 무응답자의 c형 간염 치료방법(method of treating hepatitis c in non-pesponders to interferon treatment)
FI924215A0 (fi) Anvaendningen av il-4 foer oekning av immunreaktionen foerorsakad infektiosa antigen aemnen.